Becton Dickinson Vitals Drop: Analysts ‘Have Been Wrong’ On This Med Tech Stock For Years

All NewsMay 2, 2025

Becton Dickinson receives multiple downgrades as analysts cite weakening organic growth and trimmed price targets following a Q2 update.

Latest Ratings for BDX

DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Feb 2022SVB LeerinkMaintainsMarket Perform Jan 2022Morgan StanleyMaintainsOverweight

View More Analyst Ratings for BDX

View the Latest Analyst Ratings

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent